- Home
- / NLS Pharmaceutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
NLS Pharmaceutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$4.1
2024-10-29
Market Capitalization
$10.2 M
2024-10-29
CreditSafe Score
?
Score changed on Jul 12, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross profit | 10.0K | |||||||
| General and administrative expense | 2.0M | 2.5M | 2.2M | |||||
| Operating expense total | 3.4M | 4.2M | 2.3M | 11.9M | 16.4M | 12.0M | 1.7M | 2.5M |
| Depreciation and amortization | 10.0K | 11.0K | 11.0K | 413.0K | 55.0K | |||
| EBITDA | (11.9M) | (16.4M) | (12.0M) | (1.7M) | (2.5M) | |||
| EBIT | (3.4M) | (4.2M) | (2.3M) | (11.9M) | (16.4M) | (12.0M) | (2.1M) | (2.6M) |
| Interest expense | 992.0 | 68.0K | 101.0K | 145.0K | 5.1M | 6.1M | ||
| Pre tax profit | (11.9M) | (16.5M) | (12.2M) | (7.2M) | (8.3M) | |||
| Income tax expense | 384.3K | |||||||
| Net Income | (5.1M) | (5.4M) | (2.9M) | (11.9M) | (16.5M) | (12.2M) | (7.2M) | (8.3M) |
| EPS | (0.8) | (0.8) |